The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy
Abstract
Glioblastoma multiforme (GBM) remains incurable despite aggressive implementation of multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a narrow margin around the initial resected lesion due to postsurgery residual glioma stem cells (GSCs). Tracking and eradicating postsurgery residual GSCs is critical for preventing postoperative relapse of this devastating disease, yet effective strategies remain elusive. Here, we report a cavity-injectable nanoporter-hydrogel superstructure that creates GSC-specific chimeric antigen receptor (CAR) macrophages/microglia (MΦs) surrounding the cavity to prevent GBM relapse. Specifically, we demonstrate that the CAR gene–laden nanoporter in the hydrogel can introduce GSC-targeted CAR genes into MΦ nuclei after intracavity delivery to generate CAR-MΦs in mouse models of GBM. These CAR-MΦs were able to seek and engulf GSCs and clear residual GSCs by stimulating an adaptive antitumor immune response in the tumor microenvironment and prevented postoperative glioma relapse by inducing long-term antitumor immunity in mice. In an orthotopic patient–derived glioblastoma humanized mouse model, the combined treatment with nanoporter-hydrogel superstructure and CD47 antibody increased the frequency of positive immune responding cells and suppressed the negative immune regulating cells, conferring a robust tumoricidal immunity surrounding the postsurgical cavity and inhibiting postoperative glioblastoma relapse. Therefore, our work establishes a locoregional treatment strategy for priming cancer stem cell–specific tumoricidal immunity with broad application in patients suffering from recurrent malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
The role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785
Brain immunology and immunotherapy in brain tumours
Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 722
Friebel, E., Kapolou, K., Unger, S., Núñez, N. G., Utz, S., Rushing, E. J., Regli, L., Weller, M., Greter, M., Tugues, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.055 · Cited by 685
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O’Rourke, T., Narayanan, S., Papadopoulos, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02018 · Cited by 599
Immune Microenvironment in Glioblastoma Subtypes
Chen, Z., & Hambardzumyan, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01004 · Cited by 432
Gholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2968 · Cited by 426
Targeting glioma stem cells through combined BMI1 and EZH2 inhibition
Jin, X., Kim, L. J. Y., Wu, Q., Wallace, L. C., Prager, B. C., Sanvoranart, T., Gimple, R. C., Wang, X., Mack, S. C., Miller, T. E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4415 · Cited by 383
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338
Self-citationOncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
Friedman, G. K., Johnston, J. M., Bag, A. K., Bernstock, J. D., Li, R., Aban, I., Kachurak, K., Nan, L., Kang, K.-D., Totsch, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024947 · Cited by 328
The Glioma Stem Cell Model in the Era of Single-Cell Genomics
Suvà, M. L., & Tirosh, I. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.001 · Cited by 326
Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection
Zhang, J., Chen, C., Li, A., Jing, W., Sun, P., Huang, X., Liu, Y., Zhang, S., Du, W., Zhang, R., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00843-7 · Cited by 305
Self-citationMicroglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology
Gutmann, D. H., & Kettenmann, H. (2019) · Neuron · doi:10.1016/j.neuron.2019.08.028 · Cited by 295
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Li, Z., Ding, Y., Liu, J., Wang, J., Mo, F., Wang, Y., Chen-Mayfield, T.-J., Sondel, P. M., Hong, S., & Hu, Q. (2022) · Nature Communications · doi:10.1038/s41467-022-29388-0 · Cited by 195
Self-citationThe Rational Development of CD133-Targeting Immunotherapies for Glioblastoma
Vora, P., Venugopal, C., Salim, S. K., Tatari, N., Bakhshinyan, D., Singh, M., Seyfrid, M., Upreti, D., Rentas, S., Wong, N., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.008 · Cited by 188
Dai, H., Tong, C., Shi, D., Chen, M., Guo, Y., Chen, D., Han, X., Wang, H., Wang, Y., & Shen, P. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846926 · Cited by 179
Kadiyala, P., Carney, S. V., Gauss, J. C., Garcia-Fabiani, M. B., Haase, S., Alghamri, M. S., Núñez, F. J., Liu, Y., Yu, M., Taher, A. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139542 · Cited by 151
Self-citationBrierley, C. K., Staves, J., Roberts, C., Johnson, H., Vyas, P., Goodnough, L. T., & Murphy, M. F. (2019) · Transfusion · doi:10.1111/trf.15397 · Cited by 115
Oncolytic measles virus strains have significant antitumor activity against glioma stem cells
Allen, C., Opyrchal, M., Aderca, I., Schroeder, M. A., Sarkaria, J. N., Domingo‐Musibay, E., Federspiel, M. J., & Galanis, E. (2012) · Gene Therapy · doi:10.1038/gt.2012.62 · Cited by 112
Jiang, X., Fitch, S., Wang, C. Y., Wilson, C., Li, J., Grant, G. A., & Yang, F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615396113 · Cited by 100
Self-citationCancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
Masoumi, J., Jafarzadeh, A., Abdolalizadeh, J., Khan, H. Z., Jeandet, P., Mirzaei, H., & Mirzaei, H. R. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.015 · Cited by 90
Verma, B., & Wesa, A. K. (2020) · Current Protocols in Pharmacology · doi:10.1002/cpph.77 · Cited by 74
INTRAGO: intraoperative radiotherapy in glioblastoma multiforme – a Phase I/II dose escalation study
Giordano, F. A., Brehmer, S., Abo‐Madyan, Y., Welzel, G., Sperk, E., Keller, A., Schneider, F. W., Clausen, S., Herskind, C., Schmiedek, P., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-992 · Cited by 57
Tham, M., Khoo, K., Yeo, K. P., Kato, M., Prévost‐Blondel, A., Angeli, V., & Abastado, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3127 · Cited by 50
Therapeutically reeducating macrophages to treat GBM
Garris, C., & Pittet, M. J. (2013) · Nature Medicine · doi:10.1038/nm.3355 · Cited by 42
Maclean, F. L., Ims, G. M., Horne, M. K., Williams, R. J., & Nisbet, D. R. (2018) · Advanced Materials · doi:10.1002/adma.201805209 · Cited by 41
Surgical adhesions: A sticky macrophage problem
Herrick, S. E., & Allen, J. E. (2021) · Science · doi:10.1126/science.abg5416 · Cited by 25
Cited by
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics
Wei, D., Sun, Y., Zhu, H., & Fu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.3c06019 · Cited by 303
Self-citation
Metadata
- Authors
- Chen, C., Jing, W., Chen, Y., Wang, G., Abdalla, M., Gao, L., Han, M., Shi, C., Li, A., Sun, P., Jiang, X., Yang, Z., Zhang, S., Zhang, J., Tang, C., Liu, Y., Zhang, R., Xu, F., Dong, B., Li, X., Liu, M., Qiang, B., Sun, Y., Wei, X., Li, J., Hu, Q., & Jiang, X.
- Venue
- Science Translational Medicine
- Published
- 2022-08-03
- Volume
- 14
- Issue
- 656
- Pages
- eabn1128-eabn1128
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4289638094
- Cited by
- 291
- References
- 40
- FWCI
- 29.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.